Correlation of BRAF V600E mutation with the clinicopathological features of papillary thyroid carcinoma
10.3760/cma.j.issn.1006-9801.2018.04.005
- VernacularTitle:BRAF V600E基因突变与甲状腺乳头状癌临床病理特征的相关性
- Author:
Yunfeng BO
1
;
Yanfeng XI
;
Zhuanzhuan YU
;
Jing LI
;
Yuanyuan ZHAO
;
He LI
;
Enwei XU
Author Information
1. 山西省肿瘤医院病理科
- Keywords:
Thyroid neoplasms;
Carcinoma;
papillary;
BRAF V600E mutation;
Polymerase chain reaction
- From:
Cancer Research and Clinic
2018;30(4):237-240
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the BRAF V600E mutation rate in papillary thyroid carcinoma (PTC) and its relationship with the clinicopathological features. Methods Two hundred and sixty-five PTC patients(including 226 cases of classical type,29 cases of follicular type, 3 cases of high cell type, 2 cases of diffuse sclerosis type, 2 cases of eosinophilic type, 3 cases of cystic type) from August 2014 to October in Shanxi Provincial Cancer Hospital, were collected with completely clinical and pathological information. The BRAF V600E mutation was detected by real-time polymerase chain reaction (RT-PCR) method. Pearson χ 2 test and the exact probability method were used to analysis the relationship between gene mutations and clinicopathological data. Results BRAF V600E mutation rate in PTC patients was 73.21 %(194/265). There was no significant difference in the mutation rate of BRAF V600E among patients with different age, gender, tumor location,tumor number and extravaginal invasion(all P>0.05),but the mutation rates of BRAF V600E gene in patients with different tumor size, histopathological subtypes, lymph node metastasis and clinical stage were significantly different(all P<0.05).Conclusion The PTC patients with positive BRAF V600E mutation have poor clinicopathological features,and BRAF V600E mutation may be a predictor of advanced PTC.
